Deals in Depth: June/July 2008
June/July 2008 dealmaking highlights: GSK is banking on insomnia with a $560mm pre-commercial value deal for Actelion's Phase III almorexant; Teva expands its hold on worldwide generics through the $8.7bn purchase of Barr; tying PIPEs for the second-most highest biopharma financing type was the Other category, consisting of TPG-Axon's $300mm investment in Lilly to support AD trials; and late VC money dominates medical device financing, accounting for 45% of the $744mm total.
You may also be interested in...
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.